Canada's Weston Family Buys Boots for $8.9bn: Explained

Canada’s Weston family has agreed to buy UK pharmacy and beauty retailer Boots for $8.9bn (£6.74bn), the companies announced on Wednesday. The acquisition by Wittington Investments, the Weston family’s holding company, covers Boots’ UK and Irish retail operations, its Boots Opticians chain, the No7 beauty brand and a franchise arm in Thailand. It ends the involvement of long-term backer Stefano Pessina and private equity firm Sycamore Partners.

Who Is Buying Boots and Why Now?

The Weston family controls Wittington Investments, which already owns Associated British Foods and, until its 2022 sale, the Selfridges department store group. The Weston family also controls Canada’s Loblaws and Shoppers Drug Mart, giving it direct experience in pharmacy-led retail. Galen Weston, chair of Wittington, is expected to become Boots chair. He said the family is committed to long-term ownership and significant capital investment in the Nottingham-based chain.

The deal is backed by Canadian investment firm Fairfax Financial Holdings. Wittington will hold operational control at closing, according to Personal Care Insights. The Westons previously owned the Selfridges chain before selling it for £4bn in 2022.

What the $8.9bn Boots Deal Includes

The transaction, valued at $8.9bn including assumed debt, transfers a portfolio of retail and healthcare assets to the Canadian buyers.

Key Assets in the Sale

• Boots’ UK and Irish retail stores, totalling 1,800 UK outlets and about 50,000 employees
• Boots Opticians
• No7 Beauty Company
• Boots’ Thailand and franchised businesses

Pessina and his family, along with Sycamore Partners, will retain Boots’ interests in Mexico’s Farmacias Benavides and Germany’s Alliance Healthcare Deutschland.

Why Boots Is Changing Hands Again

Boots has cycled through several owners since 2006, when it merged with Alliance UniChem. Sycamore Partners took control in 2025 through its $23.7bn takeover of Walgreens Boots Alliance and split Boots into a standalone private company. The failed $10bn attempt to sell Boots to Australia’s Sigma Healthcare earlier highlighted the difficulties of finding a buyer for a high-street pharmacy chain facing cost pressures and UK retail challenges.

Boots has closed more than 300 UK outlets in recent years, but its financial performance has been resilient. Revenue rose 3.2% to £7.5bn in the year to August 2025, with pre-tax profit up 25% to £337m, according to the Guardian.

What the Weston Takeover Means for Boots, Staff and the High Street

The sale transfers a major UK high street institution to North American owners amid ongoing pressures on pharmacy funding and retail footfall. Wittington has said it plans to upgrade stores, improve the online experience and expand healthcare services. The Weston family’s record with Associated British Foods and Primark suggests a long-term, operational approach rather than rapid cost-cutting.

Richard Hyman, a UK retail analyst, called the Westons Boots’ most encouraging owners in years. However, the deal still requires regulatory approval and is expected to close in the first quarter of 2027.

FAQ: Canada’s Weston Family Buys Boots

Who is buying Boots?

Wittington Investments, the holding company of Canada’s Weston family, is buying Boots with backing from Fairfax Financial Holdings.

How much is the Boots deal worth?

The acquisition is valued at $8.9bn (£6.74bn), including assumed debt.

What does the deal include?

It covers Boots’ UK and Irish retail operations, Boots Opticians, No7 Beauty Company and its Thailand franchise business.

When will the Boots sale close?

Subject to regulatory approval, the transaction is expected to close in the first quarter of 2027.

What happens to Stefano Pessina?

Long-term backer Stefano Pessina and Sycamore Partners will exit the UK business but retain Boots’ Mexican and German assets.

Conclusion: A New Chapter for a 177-Year-Old Retailer

Founded in Nottingham in 1849, Boots is one of Britain’s most recognisable retailers. The Weston family’s $8.9bn purchase marks a decisive ownership change and a test of whether patient, family-backed capital can revive a high-street pharmacy chain navigating digital disruption, NHS funding constraints and shifting consumer habits. For employees and customers, the immediate priority will be continuity, but Wittington’s stated investment plans signal a potential upgrade of stores and digital services over the next three years.